Michael Chorny

Dr. Michael Chorny

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2010 in Journal of Controlled Release
Verified
Journal Article
Closed access
MCMichael Chorny
Michael Chorny
EHElizabeth Hood
Elizabeth Hood
RLRobert J. Levy
Robert J. Levy
VMVladimir R. Muzykantov
Vladimir R. Muzykantov

30 June 2011 in IUBMB Life
Verified
Journal Article
Closed access
PDF file
MCMichael Chorny
Michael Chorny
IFIlia Fishbein
Ilia Fishbein
SFScott Forbes
Scott Forbes
IAIvan Alferiev
Ivan Alferiev

1 May 2015 in Biomaterials
Verified
Journal Article
Closed access
IAIvan S. Alferiev
Ivan S. Alferiev
RIRadhika Iyer
Radhika Iyer
JCJamie L. Croucher
Jamie L. Croucher
RARichard F. Adamo
Richard F. Adamo
KZKehan Zhang
Kehan Zhang
MCMichael Chorny
Michael Chorny

1 January 2016 in Journal of Controlled Release
Verified
Journal Article
Closed access
RARichard F. Adamo
Richard F. Adamo
IFIlia Fishbein
Ilia Fishbein
KZKehan Zhang
Kehan Zhang
JWJustin Wen
Justin Wen
RLRobert J. Levy
Robert J. Levy
MCMichael Chorny
Michael Chorny

13 February 2013 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
MCMichael Chorny
Michael Chorny
IFIlia Fishbein
Ilia Fishbein
JTJillian E. Tengood
Jillian E. Tengood
RARichard F. Adamo
Richard F. Adamo
IAIvan S. Alferiev
Ivan S. Alferiev
RLRobert J. Levy
Robert J. Levy
Gene therapeutic strategies have shown promise in treating vascular disease. However, their translation into clinical use requires pharmaceutical carriers enabling effective, site‐specific delivery as well as providing sustained transgene expression in blood vessels. While replication‐deficient adenovirus (Ad) offers several important advantages as a vector for vascular gene therapy, its clinical applicability is limited by rapid inactivation, suboptimal transduction efficiency in vascular cells, and serious systemic adverse effects. We hypothesized that novel zinc oleate‐based magnetic nanoparticles (MNPs) loaded with Ad would enable effective arterial cell transduction by shifting vector processing to an alternative pathway, protect Ad from inactivation by neutralizing factors, and allow site‐specific gene transfer to arteries treated with stent angioplasty using a 2‐source magnetic guidance strategy. Ad‐loaded MNPs effectively transduced cultured endothelial and smooth muscle cells under magnetic conditions compared to controls and retained capacity for gene transfer after exposure to neutralizing antibodies and lithium iodide, a lytic agent causing disruption of free Ad. Localized arterial gene expression significantly stronger than in control animal groups was demonstrated after magnetically guided MNP delivery in a rat stenting model 2 and 9 d post‐treatment, confirming feasibility of using Ad‐loaded MNPs to achieve site‐specific transduction in stented blood vessels. In conclusion, Ad‐loaded MNPs formed by controlled precipitation of zinc oleate represent a novel delivery system, well‐suited for efficient, magnetically targeted vascular gene transfer.—Chorny, M., Fishbein, I., Tengood, J. E., Adamo, R. F., Alferiev, I. S., Levy, R. J. Site‐specific gene delivery to stented arteries using magnetically guided zinc oleate‐based nanoparticles loaded with adenoviral vectors. FASEB J. 27, 2198–2206 (2013). www.fasebj.org

1 September 2006 in Molecular Therapy
Verified
Journal Article
Open access
MCMichael Chorny
Michael Chorny
Ilia FishbeinIlia Fishbein
Ilia Fishbein
IAIvan Alferiev
Ivan Alferiev
ONOrigene Nyanguile
Origene Nyanguile
RGRichard Gaster
Richard Gaster
RLRobert J. Levy
Robert J. Levy
The present studies investigated the hypothesis that affinity immobilization of replication-defective adenoviruses (Ad) on the surfaces of biodegradable nanoparticles (NP) can improve transduction through uncoupling cellular uptake from the coxsackie-adenovirus receptor (CAR). Ad was tethered to the surfaces of polylactide-based NP that were surface-activated using a photoreactive polyallylamine-benzophenone-pyridyldithiocarboxylate polymer, which enabled (via thiol chemistry) the covalent attachment of Ad-binding proteins, either the recombinant D1 domain of CAR or an adenoviral knob-specific monoclonal antibody. Gene transfer by NP-Ad complexes was studied in relation to cellular uptake as a function of cell type and the character of NP-Ad binding. NP-Ad complexes, but not Ad applied with or without control nonimmune IgG-modified NP, significantly increased green fluorescent protein reporter expression in endothelioma and endothelial and arterial smooth muscle cells (SMC) in direct correlation to the extent of NP-Ad internalization. CAR-independent uptake of NP-Ad was confirmed by demonstrating inhibition of free Ad- but not NP-Ad complex-mediated transduction by knob protein. Complexes formulated with an Ad encoding inducible nitric oxide synthase inhibited growth of cultured SMC to a significantly greater extent than those with (GFP)Ad or (NULL)Ad or free vector. It is concluded that Ad-specific affinity tethering to biodegradable NP can significantly increase the level of gene expression via a CAR-independent uptake mechanism.